Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rimegepant ODT PRN Long-term Safety in Migraine (China)
CTR20220692Phase 3Completed
- Sponsor
- Biohaven Ltd.
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of rimegepant in migraine, sponsored by Biohaven Ltd.. Started Mar 2022; status: completed.
02
Drugs
rimegepant
03
Conditions
migraine
Beyond the preview
Go deeper on CTR20220692.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220692.